203 related articles for article (PubMed ID: 32394515)
1. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
Yoshida S; Shiraishi K; Mito T; Sayama K
Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
[No Abstract] [Full Text] [Related]
2. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
[No Abstract] [Full Text] [Related]
3. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
4. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Witmer MT
Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
[TBL] [Abstract][Full Text] [Related]
6. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
[No Abstract] [Full Text] [Related]
7. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
Wang JN; Zhang Y; Huang CY; Li K; Yu XB
BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
[TBL] [Abstract][Full Text] [Related]
8. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
9. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
Rapisuwon S; Izar B; Batenchuk C; Avila A; Mei S; Sorger P; Parks JM; Cooper SJ; Wagner D; Zeck JC; Charabaty AJ; Atkins MB
J Immunother Cancer; 2019 Mar; 7(1):61. PubMed ID: 30832716
[TBL] [Abstract][Full Text] [Related]
10. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.
Arai T; Harada K; Usui Y; Irisawa R; Tsuboi R
J Dermatol; 2017 Aug; 44(8):975-976. PubMed ID: 27649838
[No Abstract] [Full Text] [Related]
11. Vogt-Koyanagi-Harada disease-like uveitis induced by vemurafenib for metastatic cutaneous malignant melanoma.
Fusumae T; Kamiya K; Maekawa T; Komine M; Murata S; Inoda S; Takahashi R; Kawashima H; Ohtsuki M
J Dermatol; 2018 Jun; 45(6):e159-e160. PubMed ID: 29314171
[No Abstract] [Full Text] [Related]
12. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
[No Abstract] [Full Text] [Related]
13. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
14. [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
Mihailovic N; Dyballa J; Herz S; Fluck M; Alnawaiseh M; Merté RL; Eter N
Ophthalmologe; 2020 May; 117(5):467-471. PubMed ID: 31489479
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal triamcinolone acetonide in Vogt-Koyanagi-Harada syndrome.
Karacorlu M; Arf Karacorlu S; Ozdemir H
Eur J Ophthalmol; 2006; 16(3):481-3. PubMed ID: 16761256
[TBL] [Abstract][Full Text] [Related]
16. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
17. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
[TBL] [Abstract][Full Text] [Related]
18. Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma.
Scovell JM; Benz K; Samarska I; Kohn TP; Hooper JE; Matoso A; Herati AS
JAMA Oncol; 2020 Aug; 6(8):1297-1299. PubMed ID: 32556068
[TBL] [Abstract][Full Text] [Related]
19. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
20. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
